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Letter to the Editor
Questioning the Effectiveness of Oral Cholera Vaccine in Port-au-Prince Slums
Dear Sir:
Oral cholera vaccination (OCV) has been validated by the
World Health Organization (WHO) as a valuable tool to com-
plement water, sanitation, and hygiene (WASH) activities in
cholera prevention for high-risk areas and populations.1 We
read with great interest the recent study published by Sévère
and others,2 which evaluated the effectiveness of a mass OCV
campaign targeting approximately 70,000 inhabitants in sev-
eral slums of Port-au-Prince, Haiti, between April and June
2012. The authors reported a 75% vaccine coverage and,
using a cohort design, a striking 97.5% vaccine effectiveness
in the 37 months postvaccination, whereas controlled clini-
cal trials have measured OCV vaccine efficacy around 57%
[95% confidence interval, 44–67%] during the first 2 years.3
Although it was expected that 56% of cholera cases would
occur among vaccinated individuals according to the WHO
screening method,4 the same proportion was 5% in the Sévère
and others cohort.
A thorough analysis of this study shows that the authors
did not evaluate the isolated effectiveness of OCV. They
rather estimated its combined effectiveness together with
WASH-associated measures. To assess the importance of such
methodological bias, we computed provided data using a bias-
indicator cohort analysis, as previously described in another
OCV campaign,5 and found that their strategy exhibited a
95% effectiveness [93–97%] against noncholeric diarrheas as
well. Pondering such bias would require adjusting the results
on the observance of WASH prevention methods, which may
have differed between nonvaccinated and vaccinated groups.
A cohort study requires that the population be carefully
defined and monitored. Conversely, cholera surveillance of
both groups was only passively conducted from the GHESKIO
(The Haitian Group for the Study of Kaposi’s Sarcoma and
Opportunistic Infections) cholera treatment center (CTC),
and many cholera cases may have been treated elsewhere.
During the study period, at least seven CTCs operated in
Port-au-Prince within a 5-mile radius around GHESKIO,
including three major CTCs operated by Medecins Sans
Frontières, and over 20,000 suspected cholera cases were
reported to the Haitian Ministry of Public Health and Popu-
lation.6 In addition, the OCV campaign was conducted from
April to July 2012, during the main cholera peak of the study
period. As the authors started to record cholera cases from
April, the cholera attack rate of the nonvaccinated group
was overestimated.
Therefore, Sévère and others should have rather conducted
a case-control study. Field effectiveness of OCV has previ-
ously been evaluated with a test negative case-control design
using participant-based analysis with censoring for cholera.7
Computing such an analysis using the study data with non-
choleric diarrheas as the control group, we found an OCV
effectiveness of 67% (41–82%), which is close to the 58%
effectiveness (13–80%) of a concomitant OCV campaign con-
ducted in rural Haiti using the same vaccine.8
Field reports of OCV campaigns can be interesting to eval-
uate the feasibility and impact of such strategies. Estimating
vaccine effectiveness is also important to detect unexpected
programmatic errors. However, vaccine effectiveness results
are hampered by many biases that are difficult to ponder in
observational studies. Consequently, effectiveness results shall
neither be confounded with the experimentally measured vac-
cine efficacy, nor replace the proper evaluation of vaccine
impact on the course of an epidemic.
Finally, as stated by the WHO position paper on cholera
vaccines1 and suggested by our additional analysis of Sévère
and others data, WASH activities remain the corner stone of
cholera control and elimination strategies. In Haiti, money is
currently lacking to sustain the nationwide reactive program
of community awareness and water treatment, and only a tiny
fraction of the resources requested by the National Plan for
Cholera Elimination in Haiti, 2013–20229 for long-term water
and sanitation infrastructures has been pledged so far. Such
spectacular but biased OCV effectiveness results shall not
even more divert stakeholders and donors from funding these
crucial short and long-term WASH programs.
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